Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has granted inducement equity awards to two new employees. The compensation package includes 6,200 stock options at an exercise price of $3.17 per share and 3,100 RSUs.
The stock options will vest over four years with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years with 33 1/3% vesting annually. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.
["Ability to attract new talent with equity compensation", "Structured vesting schedule promotes employee retention"]Protara Therapeutics (Nasdaq: TARA), società in fase clinica che sviluppa terapie per il cancro e le malattie rare, ha assegnato premi azionari d'induzione a due nuovi dipendenti. Il pacchetto prevede 6.200 opzioni con prezzo di esercizio di $3,17 per azione e 3.100 RSU.
Le opzioni si matureranno in quattro anni: il 25% dopo il primo anno e il resto mensilmente nei successivi 36 mesi. Le RSU si matureranno in tre anni con il 33,33% annuale. Queste assegnazioni sono state approvate ai sensi della Nasdaq Listing Rule 5635(c)(4) come incentivi materiali per l'impiego.
Vantaggi: "Capacità di attrarre nuovi talenti tramite compensi azionari"; "Un programma di vesting strutturato favorisce la fidelizzazione dei dipendenti".
Protara Therapeutics (Nasdaq: TARA), una compañía en fase clínica centrada en terapias contra el cáncer y enfermedades raras, ha otorgado premios de acciones por incentivo a dos nuevos empleados. El paquete incluye 6.200 opciones sobre acciones con un precio de ejercicio de $3,17 por acción y 3.100 RSU.
Las opciones se consolidarán durante cuatro años: el 25% tras el primer año y el resto mensualmente durante los siguientes 36 meses. Las RSU se consolidarán en tres años con un 33,33% anual. Estas concesiones fueron aprobadas conforme a la Nasdaq Listing Rule 5635(c)(4) como incentivos materiales para el empleo.
Beneficios: "Capacidad para atraer nuevo talento mediante compensación en acciones"; "Un calendario de vesting estructurado promueve la retención de empleados".
Protara Therapeutics (Nasdaq: TARA), 암 및 희귀질환 치료제에 주력하는 임상 단계 기업은 두 명의 신입 직원에게 유인성 주식 보상을 부여했습니다. 보상 패키지에는 6,200주 스톡옵션(행사가격 주당 $3.17)과 3,100 RSU가 포함됩니다.
스톡옵션은 4년간 베스팅되며, 1년 후 25%가 베스트되고 나머지는 향후 36개월 동안 매월 베스트됩니다. RSU는 3년간 베스팅되며 매년 33.33%가 베스트됩니다. 이 부여는 고용 유인을 위한 중대한 보상으로 Nasdaq Listing Rule 5635(c)(4)에 따라 승인되었습니다.
강점: "주식 보상을 통한 인재 유치 능력"; "구조화된 베스팅 일정은 직원 유지에 기여".
Protara Therapeutics (Nasdaq: TARA), société en phase clinique spécialisée dans les thérapies contre le cancer et les maladies rares, a accordé des attributions d'actions d'incitation à deux nouveaux employés. Le package comprend 6 200 options au prix d'exercice de 3,17 $ par action et 3 100 RSU.
Les options se acquerront sur quatre ans : 25 % après un an puis le reste mensuellement sur les 36 mois suivants. Les RSU s'acquerront sur trois ans avec 33,33 % par an. Ces attributions ont été approuvées en vertu de la Nasdaq Listing Rule 5635(c)(4) comme incitations matérielles à l'emploi.
Atouts : "Capacité à attirer de nouveaux talents par une rémunération en actions" ; "Un calendrier de vesting structuré favorise la rétention des employés".
Protara Therapeutics (Nasdaq: TARA), ein klinisch fortgeschrittenes Unternehmen, das Therapien für Krebs und seltene Erkrankungen entwickelt, hat Anreiz-Aktienzuteilungen an zwei neue Mitarbeiter gewährt. Das Vergütungspaket umfasst 6.200 Aktienoptionen mit einem Ausübungspreis von $3,17 pro Aktie sowie 3.100 RSUs.
Die Optionen werden über vier Jahre vesten: 25% nach einem Jahr, der Rest monatlich über die folgenden 36 Monate. Die RSUs vesten über drei Jahre mit jeweils 33,33% pro Jahr. Diese Zuteilungen wurden gemäß Nasdaq Listing Rule 5635(c)(4) als wesentliche Anreize für die Beschäftigung genehmigt.
Vorteile: "Fähigkeit, neue Talente durch aktienbasierte Vergütung anzuziehen"; "Ein strukturiertes Vesting-Modell fördert die Mitarbeiterbindung".
- None.
- Potential dilution from new equity awards
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees.
The Compensation Committee of Protara’s Board of Directors approved an aggregate of 6,200 stock option awards and 3,100 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on September 2, 2025 and have an exercise price of
All option awards vest over four years, with
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
What equity awards did Protara Therapeutics (TARA) grant to new employees in September 2025?
What is the vesting schedule for Protara's (TARA) new employee stock options?
How do the RSUs vest for Protara's (TARA) new employees?
What was the exercise price for Protara's (TARA) inducement stock options granted in September 2025?
Why did Protara Therapeutics (TARA) issue these equity awards?
